IL Receptor
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB02865 | YM-90709 | 163769-88-8 | YM-90709 is a competitive and selective IL-5 receptor antagonist with IC50 value ranging in 0.45 - 1 mM. |
| FB09638 | Suplatast Tosylate | 94055-76-2 | Suplatast Tosylate is an inhibitor of Th2 cytokine synthesis which can attenuate IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production. |
| FB08608 | MK-571 | 115104-28-4 | MK-571 sodium is a selective, orally active CysLT1 receptor antagonist, which blocks the binding of LTD4, but not LTC4, to human and guinea pig lung membranes with Ki values of 0.22 nM and 2.1 nM, respectively. |
| FB12351 | GIBH-130 | 1252608-59-5 | GIBH-130 can suppress IL-1β secretion via activating microglia with IC50 of 3.4 nM and has effect on neuroinflammation. |
| FB11612 | Esonarimod | 101973-77-7 | Esonarimod is an antirheumatic drug and IL-1 inhibitor. |
| FB08426 | Disulfiram | 97-77-8 | Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram acts as an allosteric inhibitor of MERS-CoV PLpro but as a competitive (or mixed) inhibitor of SARS-CoV PLpro. |
| FB03862 | Diacerein | 13739-02-1 | Diacerein is a symptomatic slow-acting medicine in osteoarthritis which can reduce the level of IL-1 receptors leading to fewer receptors to form heterodimer complexes. |
| FB04108 | Dexamethasone | 50-02-2 | Dexamethasone results in decrease in transmonolayer paracellular permeability mainly to sucrose, fluorescein and dextrans of up to 20 KDa in an immortalised rat brain endothelial cell line (GPNT). |
| FB00333 | Dexamethasone Acetate | 1177-87-3 | Dexamethasone Acetate is a synthetic glucocorticoid which works as a glucocorticoid receptor agonist and an interleukin receptor modulator. |
| FB12317 | CP 424174 | 210825-31-3 | CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. |
| FB16855 | Anakinra | 143090-92-0 | Anakinra is an IL-1 receptor antagonist which is a front-line therapy for hemophagocytic lymphohistiocytosis (HLH). Anakinra might be expected to be efficacious on COVID-19 for COVID-19 resembles HLH. |